Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CLDIBearishLegalnews

High materiality7/10

NYSE American delisting risk for CLDI; plan to regain compliance by 2028

Sep 25, 2026, 5:42 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Regulatory non-compliance risk commonly pressures small-cap stocks due to liquidity concerns, potential capital needs, and execution risk around a remediation plan; historical parallels show minor-cap names often suffer volatility and multiple compression events during delisting processes.

AI summary

What happened, with direct paths to the underlying reporting

Calidi Biotherapeutics disclosed a NYSE American notice citing a stockholders’ equity deficiency and ineligibility for exemptions. CLDI must submit a plan by Oct 21, 2026 to regain compliance by Mar 21, 2028; failure could trigger delisting. The .BC suffix signals below-compliance while operations and regulatory filings continue.

NYSE American flagged CLDI for equity deficiency. A compliance plan is due Oct 21, 2026.
No exemption eligibility per rule. No market-cap exemption.
Plan submission deadline: Oct 21, 2026; delisting possible if not accepted.
Stock continues trading with .BC designation; no immediate business disruption.
CLDI's lead program CLD-401 in IND-enabling studies targets metastatic cancers.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.